Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo
FEBS Open Bio · 2025-11 · 15 (11) · 1900-1912
DOI: 10.1002/2211-5463.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 21.07.2025. Verfasst von Shengjun Fu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Insititue of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Autophagy, Indoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gansu Health Industry Research Program, Gansu Province Higher Education Innovation Fund Project, Lanzhou Youth Science and Technology Talent Innovation Project.
Abstract (Originalsprache)
Chemotherapy remains the main treatment for muscle‐invasive bladder cancer (BLCA) despite drug resistance and lack of target drugs greatly limiting long‐term survival of patients. Thus, novel and effective drugs specific to BLCA are required to aid in its treatment and improve patient survival. In the present study, we found that the compound Ro‐31‐8220, a pan‐protein kinase C inhibitor, displays potent anti‐bladder cancer efficacy in vitro and in vivo . Ro‐31‐8220 treatment suppressed bladder cancer cell migration and invasion and also induced cell apoptosis in a dose‐dependent manner. Proteomic analysis showed that Ro‐31‐8220 treatment altered the expression of numerous proteins and KEGG enrichment analysis demonstrated that multiple signal pathways are regulated by Ro‐31‐8220, including autophagy. To further validate these results, we carried out western blotting, GFP‐LC3 fusion protein and transmission electron microscopy analyses, all of which demonstrated that Ro‐31‐8220 induced bladder cancer cell autophagy. Blockade of autophagy with chloroquine, an autophagy inhibitor, attenuated Ro‐31‐8220 induced bladder cancer cell death. In a bladder cancer xenograft tumor growth mice model, we showed that intraperitoneal injection of Ro‐31‐8220 significantly decreased tumor size and tumor weight compared to the control group, suggesting an in vivo tumor suppression ability of Ro‐31‐8220 through activation of autophagy. These results suggest that Ro‐31‐8220 may be a novel promising candidate drug for bladder cancer therapy. Further studies, including clinical trials, are required to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Insititue of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
- Gansu Provincial Center for Disease Control and Prevention, Lanzhou, Gansu, China.
- The Second Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou, Gansu, China.
- Department of Clinical Medical Laboratory, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
- Pediatrics Department, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
- Second Provincial People's Hospital of Gansu, Pathology department, Affiliated hospital of Northwest Minzu University, Lanzhou, Gansu, China.
ORCID-Profile: Lanlan Li
Förderung
- Gansu Health Industry Research Program
- Gansu Province Higher Education Innovation Fund Project
- Lanzhou Youth Science and Technology Talent Innovation Project
- Natural Science Foundation Project of Gansu Province
- Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital
- Cuiying Scientific Training Program for Undergraduates of Lanzhou University Second Hospital
Zitieren
APA
Fu, S., Tao, Y., Wu, S., Gong, Y., Zhao, Y., Niu, S., Cheng, H., Mu, Y., Xu, N., Wang, Y., Lu, J., Liu, S., & Li, L. (2025). Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo. FEBS Open Bio, 15(11), 1900-1912. https://doi.org/10.1002/2211-5463.70089
Vancouver
Fu S, Tao Y, Wu S, Gong Y, Zhao Y, Niu S, et al. Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo. FEBS Open Bio. 2025;15(11):1900-1912. doi:10.1002/2211-5463.70089
BibTeX
@article{Fu2025,
author = {Fu, Shengjun and Tao, Yan and Wu, Shan and Gong, Yuwen and Zhao, Youli and Niu, Shaomin and Cheng, Hui and Mu, You and Xu, Na and Wang, Ying and Lu, Jianzhong and Liu, Shanhui and Li, Lanlan},
title = {Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo},
journal = {FEBS Open Bio},
year = {2025},
volume = {15},
number = {11},
pages = {1900--1912},
doi = {10.1002/2211-5463.70089}
}
EUVIMED